Our data provided preclinical evidence of the immune-related cardiomyopathy with the administration of anti-PD-1 ICIs, and thus the cardiac condition should be concerned and monitored in cancer patients treated with anti-PD-1 ICIs therapy. Here, PDCD1 is linked to cancer.